

Corrado Ficorella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7641204/publications.pdf>

Version: 2024-02-01

67
papers

1,104
citations

471509

17
h-index

454955

30
g-index

67
all docs

67
docs citations

67
times ranked

1907
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale. <i>Future Oncology</i> , 2022, 18, 771-779. | 2.4 | 3 |
| 2 | Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021, 142, 18-28. | 2.8 | 81 |
| 3 | Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. <i>International Journal of Medical Sciences</i> , 2021, 18, 2245-2250. | 2.5 | 5 |
| 4 | Influenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)., 2021, 9, e002619. | | 17 |
| 5 | Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicentre real-world study. <i>European Journal of Cancer</i> , 2021, 148, 24-35. | 2.8 | 19 |
| 6 | Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 150, 224-231. | 2.8 | 24 |
| 7 | Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, Real-Life Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2021, , . | 2.3 | 8 |
| 8 | The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. <i>Scientific Reports</i> , 2021, 11, 13770. | 3.3 | 8 |
| 9 | PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598. | 3.2 | 6 |
| 10 | Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors. <i>Supportive Care in Cancer</i> , 2020, 28, 1051-1058. | 2.2 | 0 |
| 11 | Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929. | 5.1 | 4 |
| 12 | The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings. <i>Palliative and Supportive Care</i> , 2020, 18, 33-38. | 1.0 | 4 |
| 13 | Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. <i>Lung Cancer</i> , 2020, 150, 123-131. | 2.0 | 13 |
| 14 | Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer. <i>Cancers</i> , 2020, 12, 2457. | 3.7 | 3 |
| 15 | Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future. <i>Cancers</i> , 2020, 12, 2598. | 3.7 | 11 |
| 16 | Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter SLAVE Study. <i>Cancers</i> , 2020, 12, 1259. | 3.7 | 19 |
| 17 | The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1513-1527. | 2.2 | 7 |
| 18 | Rare bone toxicity associated with vismodegib. <i>JAAD Case Reports</i> , 2020, 6, 482-485. | 0.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2. | 2.6 | 50 |
| 20 | Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDia study. <i>Immunotherapy</i> , 2020, 12, 151-159. | 2.0 | 16 |
| 21 | Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series. <i>Journal of Addictive Diseases</i> , 2020, 38, 229-234. | 1.3 | 4 |
| 22 | Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020, 128, 17-26. | 2.8 | 85 |
| 23 | Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 1094-1101. | 1.3 | 2 |
| 24 | Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , 2020, 235, 7900-7910. | 4.1 | 19 |
| 25 | Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study. <i>Scientific Reports</i> , 2020, 10, 1456. | 3.3 | 64 |
| 26 | A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2020, 12, 6107-6111. | 1.4 | 1 |
| 27 | The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study. <i>Palliative and Supportive Care</i> , 2019, 17, 82-86. | 1.0 | 4 |
| 28 | Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2365-2373. | 2.5 | 9 |
| 29 | Cancer Care After Natural Disaster: Different Countries, Similar Problems. <i>Journal of Global Oncology</i> , 2019, 5, 1-2. | 0.5 | 7 |
| 30 | <p>Weekly alternate intensive regimen FlrB/FOx in metastatic colorectal cancer patients: an update from clinical practice</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2159-2170. | 2.0 | 8 |
| 31 | What cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudes. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1439-1444. | 0.9 | 9 |
| 32 | Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. <i>Clinical Lung Cancer</i> , 2019, 20, 237-247.e1. | 2.6 | 118 |
| 33 | Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. <i>Journal of Cancer</i> , 2019, 10, 5926-5934. | 2.5 | 24 |
| 34 | Family history of cancer and DNA damage response genes: Two sides of the same coin?. <i>Thoracic Cancer</i> , 2019, 10, 401-401. | 1.9 | 1 |
| 35 | Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A hypothesis generator preliminary report. <i>Thoracic Cancer</i> , 2019, 10, 347-351. | 1.9 | 54 |
| 36 | Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor positive, advanced breast cancer: A real-world experience. <i>Journal of Cellular Physiology</i> , 2019, 234, 7708-7717. | 4.1 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Sequencing chemotherapy and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (UC): Meet-Uro1 study.. Journal of Clinical Oncology, 2019, 37, e16013-e16013. | 1.6 | 1 |
| 38 | Survivorship in young women after early breast cancer: a cross-sectional study of emotional traits along 3-years perspective. Rivista Di Psichiatria, 2019, 54, 160-167. | 0.6 | 14 |
| 39 | Multicentric retrospective analysis of platinum+epemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A snapshot from clinical practice. Thoracic Cancer, 2018, 9, 241-252. | 1.9 | 6 |
| 40 | KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease. Human Pathology, 2018, 74, 178-182. | 2.0 | 5 |
| 41 | Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study. Immunotherapy, 2018, 10, 643-655. | 2.0 | 15 |
| 42 | Where are we with treatment options after first line in small cell lung cancer? A report of two opposite cases treated with CAPTEM regimen and possible perspectives. Journal of Thoracic Disease, 2018, 10, E520-E525. | 1.4 | 0 |
| 43 | Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab. Journal of Clinical Neuromuscular Disease, 2018, 20, 99-100. | 0.7 | 2 |
| 44 | Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy. Thoracic Cancer, 2018, 9, 1623-1630. | 1.9 | 38 |
| 45 | “Palliative” or “Supportive”? Is It Just a Matter of Word?. Journal of Palliative Medicine, 2018, 21, 1546-1546. | 1.1 | 0 |
| 46 | Influenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. Immunotherapy, 2018, 10, 1229-1239. | 2.0 | 38 |
| 47 | Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen. Oncology Reports, 2018, 40, 803-812. | 2.6 | 3 |
| 48 | Intensive first-line triplet chemotherapy plus cetuximab Flr-C/FOx-C in RAS wild-type MCRC: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.. Journal of Clinical Oncology, 2018, 36, 673-673. | 1.6 | 0 |
| 49 | First-line chemotherapy with docetaxel, oxaliplatin, and timed-flat infusion 5Fluorouracil in metastatic gastro-esophageal adenocarcinomas: The experience with FD/FOx regimen.. Journal of Clinical Oncology, 2018, 36, 178-178. | 1.6 | 0 |
| 50 | Integration between Oncology and Palliative Care: A Plan for the Next Decade?. Tumori, 2017, 103, e23-e23. | 1.1 | 0 |
| 51 | A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget, 2017, 8, 56921-56931. | 1.8 | 53 |
| 52 | Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis. Oncotarget, 2017, 8, 72031-72043. | 1.8 | 6 |
| 53 | Topical menthol for treatment of chemotherapy-induced peripheral neuropathy. Indian Journal of Palliative Care, 2017, 23, 350. | 1.0 | 10 |
| 54 | Increased expression and activity of p75NTR are crucial events in azacitidine-induced cell death in prostate cancer. Oncology Reports, 2016, 36, 125-130. | 2.6 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer. <i>Bone</i> , 2016, 87, 169-175. | 2.9 | 16 |
| 56 | New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting. <i>Cancer Medicine</i> , 2016, 5, 2232-2239. | 2.8 | 7 |
| 57 | Comment on "What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain: Expert Opinion". <i>Drugs</i> , 2016, 76, 1059-1061. | 10.9 | 1 |
| 58 | The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 190-202. | 4.4 | 24 |
| 59 | Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice. <i>BioMed Research International</i> , 2014, 2014, 1-11. | 1.9 | 10 |
| 60 | Rapid Resolution of Refractory Chemotherapy-Induced Oral Mucositis With Platelet Gel-Released Supernatant in a Pediatric Cancer Patient: A Case Report. <i>Journal of Pain and Symptom Management</i> , 2014, 48, e2-e4. | 1.2 | 7 |
| 61 | Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen. <i>International Journal of Oncology</i> , 2014, 44, 1820-1830. | 3.3 | 10 |
| 62 | Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1 functional interplay. <i>International Journal of Oncology</i> , 2014, 44, 2121-2131. | 3.3 | 64 |
| 63 | c.35 G > A KRAS-mutant genotype and clinical outcome of patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 512-512. | 1.6 | 0 |
| 64 | Integrating Oncology and Palliative Home Care in Italy: The Experience of the "L'Aquila per la Vita" Home Care Unit. <i>Tumori</i> , 2013, 99, 225-228. | 1.1 | 8 |
| 65 | Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice. <i>Clinical Colorectal Cancer</i> , 2012, 11, 229-237. | 2.3 | 18 |
| 66 | Different clinical outcome of metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to KRAS genotype and disease extension.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14010-e14010. | 1.6 | 0 |
| 67 | P16 hypermethylation contributes to the characterization of gene inactivation profiles in primary gastric cancer. <i>Oncology Reports</i> , 2003, 10, 169-73. | 2.6 | 10 |